Back

Second Genome Granted U.S. Patent for Proteins for the Treatment or Prevention of Epithelial Barrier Function Disorders

Patent advances lead mucosal healing program candidate, with potential application in multiple gastrointestinal disorders BRISBANE, Calif. – December 20, 2021 – […]

Patent advances lead mucosal healing program candidate, with potential application in multiple gastrointestinal disorders

BRISBANE, Calif. – December 20, 2021 – Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers from public and proprietary microbiome data, today announced that the U.S. Patent and Trademark Office issued a U.S. patent, No. 11,174,293 B2, entitled, “Proteins for the Treatment of Epithelial Barrier Function Disorders.” The patent covers a potential first-in-class therapeutic that improves mucosal healing, and other novel proteins and pharmaceutical compositions comprising those proteins that have application in the treatment or prevention of inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, and other epithelial barrier function disorders.

“The issuance of Second Genome’s U.S. patent is another milestone in the advancement of our lead mucosal healing candidate and strengthens our overall intellectual property portfolio,” said Karim Dabbagh, Ph.D., President and Chief Executive Officer of Second Genome. “There is an opportunity to improve current IBD treatments beyond suppression of disease associated inflammation by targeting the integrity of the epithelial barrier. Second Genome’s novel proteins demonstrate the potential to act directly at the epithelial barrier to influence mucosal healing in a variety of gastrointestinal and epithelial barrier function disorders.”

Mucosal healing is a key therapeutic goal for IBD. Second Genome’s lead protein candidate targeting mucosal healing is delivered directly to the gut via an engineered L. lactis probiotic system and has the potential to address a broad patient population due to anticipated combinability with standards of care across lines of therapy in IBD. Second Genome expects to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in 2022.

Investor Contact:

Media Contact: